MyoKardia
Develops novel, small molecule therapeutics that address key clinical needs of patients with genetic heart diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD17.9b (Public information from Oct 2020)
Share price
$224.91
San Francisco California (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 11.0m | 33.0m | 10.0m | 7.0m | 26.0m | - |
| % growth | - | 200 % | (70 %) | (30 %) | 271 % | - |
| EBITDA | (57.0m) | (72.0m) | (286m) | (282m) | (322m) | (188m) |
| % EBITDA margin | (518 %) | (218 %) | (2860 %) | (4029 %) | (1238 %) | - |
| Profit | (57.0m) | (67.0m) | (276m) | (289m) | (314m) | (18.0m) |
| % profit margin | (518 %) | (203 %) | (2760 %) | (4129 %) | (1208 %) | - |
| R&D budget | - | 34.1m | 143m | - | - | - |
| R&D % of revenue | - | 103 % | 1430 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $4.0m | Early VC | |
$10.0m | Early VC | ||
$46.0m | Series B | ||
| N/A | N/A | IPO | |
* | N/A | N/A | Post IPO Equity |
$13.1b Valuation: $13.1b 1310.0x EV/LTM Revenues -45.8x EV/LTM EBITDA | Acquisition | ||
| Total Funding | CAD81.8m | ||
Related Content
Recent News about MyoKardia
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.